BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 7912565)

  • 1. Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy.
    Nicholson RI; McClelland RA; Gee JM; Manning DL; Cannon P; Robertson JF; Ellis IO; Blamey RW
    Breast Cancer Res Treat; 1994 Jan; 29(1):117-25. PubMed ID: 7912565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy.
    Archer SG; Eliopoulos A; Spandidos D; Barnes D; Ellis IO; Blamey RW; Nicholson RI; Robertson JF
    Br J Cancer; 1995 Nov; 72(5):1259-66. PubMed ID: 7577479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity.
    Nicholson RI; McClelland RA; Finlay P; Eaton CL; Gullick WJ; Dixon AR; Robertson JF; Ellis IO; Blamey RW
    Eur J Cancer; 1993; 29A(7):1018-23. PubMed ID: 8098946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy.
    Gee JM; Robertson JF; Ellis IO; Willsher P; McClelland RA; Hoyle HB; Kyme SR; Finlay P; Blamey RW; Nicholson RI
    Int J Cancer; 1994 Dec; 59(5):619-28. PubMed ID: 7960234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical studies on oncogene products (EGF-R, c-erbB-2) and growth factors (EGF, TGF-alpha) in human breast cancer: their relationship to oestrogen receptor status, histological grade, mitotic index and nodal status.
    Umekita Y; Enokizono N; Sagara Y; Kuriwaki K; Takasaki T; Yoshida A; Yoshida H
    Virchows Arch A Pathol Anat Histopathol; 1992; 420(4):345-51. PubMed ID: 1348890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptors in breast cancer: association with early relapse and death, poor response to hormones and interactions with neu.
    Harris AL; Nicholson S; Sainsbury JR; Farndon J; Wright C
    J Steroid Biochem; 1989; 34(1-6):123-31. PubMed ID: 2576295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transforming growth factor-alpha and endocrine sensitivity in breast cancer.
    Nicholson RI; McClelland RA; Gee JM; Manning DL; Cannon P; Robertson JF; Ellis IO; Blamey RW
    Cancer Res; 1994 Apr; 54(7):1684-9. PubMed ID: 8137282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer.
    Wright C; Nicholson S; Angus B; Sainsbury JR; Farndon J; Cairns J; Harris AL; Horne CH
    Br J Cancer; 1992 Jan; 65(1):118-21. PubMed ID: 1346366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.
    Leitzel K; Teramoto Y; Konrad K; Chinchilli VM; Volas G; Grossberg H; Harvey H; Demers L; Lipton A
    J Clin Oncol; 1995 May; 13(5):1129-35. PubMed ID: 7738618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Receptor status, proliferating activity, and c-erbB2 oncoprotein. An immunocytochemical evaluation in breast cancer.
    Campani D; Sarnelli R; Fontanini G; Martini L; Cecchetti D; De Luca F; Squartini F
    Ann N Y Acad Sci; 1993 Nov; 698():167-73. PubMed ID: 7904137
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunohistochemical expression of c-erbB-2 oncoprotein and EGF-R in pre- and postmenopausal breast cancer.
    Ratnakar N; Sharma BK; Chaturvedi KU; Kaur S; Naik SL; Ray A
    APMIS; 1998 Nov; 106(11):1075-80. PubMed ID: 9890270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multiparametric study on the prognostic value of epidermal growth factor receptor in operable breast carcinoma.
    Gasparini G; Boracchi P; Bevilacqua P; Mezzetti M; Pozza F; Weidner N
    Breast Cancer Res Treat; 1994 Jan; 29(1):59-71. PubMed ID: 7912568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogene proteins and proliferation antigens in thymomas: increased expression of epidermal growth factor receptor and Ki67 antigen.
    Gilhus NE; Jones M; Turley H; Gatter KC; Nagvekar N; Newsom-Davis J; Willcox N
    J Clin Pathol; 1995 May; 48(5):447-55. PubMed ID: 7629292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of four oestrogen-responsive genes, pLIV1, pS2, pSYD3 and pSYD8, in predicting responsiveness to endocrine therapy in primary breast cancer.
    Manning DL; McClelland RA; Gee JM; Chan CM; Green CD; Blamey RW; Nicholson RI
    Eur J Cancer; 1993; 29A(10):1462-8. PubMed ID: 8398276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of two oestrogen receptor assays in the prediction of the clinical course of patients with advanced breast cancer.
    Robertson JF; Bates K; Pearson D; Blamey RW; Nicholson RI
    Br J Cancer; 1992 May; 65(5):727-30. PubMed ID: 1534019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative endocrine therapy with goserelin acetate and tamoxifen in hormone receptor-positive premenopausal breast cancer patients.
    Shimizu D; Ishikawa T; Tanabe M; Sasaki T; Ichikawa Y; Chishima T; Endo I
    Breast Cancer; 2014 Sep; 21(5):557-62. PubMed ID: 23184499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of epidermal growth factor receptor in breast cancer, from early stages to advanced disease.
    Nesković-Konstantinović Z; Nikolić-Vukosavljević D; Branković-Magić M; Kanjer K; Gavrilović D; Mitrović L; Borojević N; Vukotić D; Spuzić I
    J Exp Clin Cancer Res; 1999 Sep; 18(3):347-55. PubMed ID: 10606181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: results of a 10 year follow-up study.
    Klijn JG; Look MP; Portengen H; Alexieva-Figusch J; van Putten WL; Foekens JA
    Breast Cancer Res Treat; 1994 Jan; 29(1):73-83. PubMed ID: 8018964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients.
    Soubeyran I; Quénel N; Coindre JM; Bonichon F; Durand M; Wafflart J; Mauriac L
    Br J Cancer; 1996 Oct; 74(7):1120-5. PubMed ID: 8855985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationships between epidermal growth factor receptor (EGF-R) and other predictors of prognosis in breast carcinomas. An immunohistochemical study.
    Martinazzi M; Crivelli F; Zampatti C; Martinazzi S
    Pathologica; 1993; 85(1100):637-44. PubMed ID: 8170712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.